Research News on Targeted Therapies
-
Avastin-Abraxane Combo May Treat Triple-Negative Breast Cancer
Research in mice suggests that Avastin combined with Abraxane works better against triple-negative breast cancer cells than Abraxane alone.
-
Too Much MicroRNA Linked to Herceptin Resistance
New research suggests that too much microRNA-21 in HER2-positive breast cancer cells is linked to Herceptin resistance.
-
Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer
Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.
-
Herceptin May Destroy Cancer Stem Cells
Preliminary research using math formulas suggests that HER2-negative breast cancers may benefit from Herceptin.
-
HER2 Levels Drop If HER2-Positive Cancers Respond to Chemo Plus Herceptin Before Surgery
New research suggests that measuring the drop in blood HER2 protein levels before and after chemotherapy and Herceptin given before surgery may help predict which women are most likely to benefit from Herceptin treatment before surgery.
-
Avastin Helps Stop Growth of Metastatic Breast Cancer
Research suggests adding Avastin to chemotherapy as the first treatment for metastatic breast cancer increases the length of time before the cancer grows.
-
FDA Approves Tykerb-Femara Combo to Treat Advanced-Stage Disease
The FDA has approved the combination of Tykerb and Femara to treat post-menopausal women diagnosed with hormone-receptor-positive, HER2-positive advanced-stage breast cancer.
-
Herceptin Plus Chemo Before Surgery Better Than Chemo Alone for HER2-Positive Locally-Advanced Disease
Research suggests that giving Herceptin at the same time as chemotherapy BEFORE surgery for HER2-positive locally advanced or inflammatory breast cancer can lengthen the time before the cancer comes back or grows compared to chemotherapy alone.
-
Herceptin Plus Tykerb Improves Survival for Women with Metastatic HER2-Positive Breast Cancer
HER2-positive, metastatic breast cancer that grows while being treated with Herceptin seems to benefit from adding Tykerb to the Herceptin rather than switching from Herceptin to Tykerb.
-
Experimental Combo of Herceptin and Maytansine May Help Treat Metastatic HER2-Positive Breast Cancer
An experimental treatment combining Herceptin and maytansine shows some promise for treating metastatic breast cancer.
